(Q36634221)

15 August 2017

1 reference

title

Role of P-glycoprotein in statin drug interactions (English)

1 reference

15 August 2017

Carol W Holtzman

1

1 reference

15 August 2017

Barbara S Wiggins

series ordinal

2

1 reference

15 August 2017

Sarah A Spinler

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

26

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1601-1607

1 reference

Safety of statins: focus on clinical pharmacokinetics and drug interactions

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

FDA adverse event reports on statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Role of P-glycoprotein in pharmacokinetics: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Functional interactions between P-glycoprotein and CYP3A in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Biochemistry of multidrug resistance mediated by the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Transporters and their impact on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

The physiological function of drug-transporting P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

HMG-CoA reductase inhibitors and P-glycoprotein modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Simvastatin and lovastatin, but not pravastatin, interact with MDR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

The interaction of diltiazem with simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Effect of itraconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

The effect of erythromycin on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

St Johns wort increases expression of P-glycoprotein: implications for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

MDR1 genotype-related pharmacokinetics and pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.11.1601

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.11.1601

1 reference

15 August 2017

1 reference